JEFFREY M LEIDEN, M.D.
Osteopathic Medicine at Abbott Park Rd, North Chicago, IL
License number
Illinois 50631
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
2
100 Abbott Park Rd, North Chicago, IL 60064
196 Beach Rd, Glencoe, IL 60022
196 Beach Rd, Glencoe, IL 60022
Phone
(847) 938-9313
Personal information
See more information about JEFFREY M LEIDEN at radaris.comName
Address
Phone
Glencoe, IL
55 Crescent Dr, Glencoe, IL 60022
196 Beach Rd, Glencoe, IL 60022
1189 Oakley Ave, Winnetka, IL 60093
51 Crescent Dr, Glencoe, IL 60022
Professional information
See more information about JEFFREY M LEIDEN at trustoria.com
Dr. Jeffrey M Leiden, Abbott Park IL - MD (Doctor of Medicine)
Dr. Jeffrey M Leiden, Abbott Park IL - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
100 Abbott Park Rd, Abbott Park 60064
(847) 938-9313 (Phone)
270 Barton Shore Dr, Ann Arbor 48105
(847) 938-9313 (Phone)
270 Barton Shore Dr, Ann Arbor 48105
Certifications:
Cardiovascular Disease, 1987, Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
100 Abbott Park Rd, Abbott Park 60064
270 Barton Shore Dr, Ann Arbor 48105
Brigham and Women's Hospital
75 Francis St, Boston 02115
270 Barton Shore Dr, Ann Arbor 48105
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1981
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1981
Jeffrey M Leiden, Chicago IL
Jeffrey M Leiden, Chicago IL
Specialties:
Internist
Address:
5841 S Maryland Ave, Chicago, IL 60637
100 Abbott Park Rd, Abbott Park, IL 60064
100 Abbott Park Rd, Abbott Park, IL 60064
Education:
University of Chicago, Pritzker School of Medicine - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Mouse Model For Congestive Heart Failure
Mouse Model For Congestive Heart Failure
US Patent:
6194632, Feb 27, 2001
Filed:
Dec 18, 1998
Appl. No.:
9/215098
Inventors:
Jeffrey M. Leiden - Glencoe IL
International Classification:
A01K 6700, A01K 67027, C12N 1500, G01N 3300
US Classification:
800 3
Abstract:
The present invention relates to transgenic mice which express CREB. These transgenic mice provide a genetic model of dilated cardiomyopathy.
Adenovirus-Medicated Gene Transfer To Cardiac And Vascular Smooth Muscle
Adenovirus-Medicated Gene Transfer To Cardiac And Vascular Smooth Muscle
US Patent:
6436907, Aug 20, 2002
Filed:
Nov 5, 1998
Appl. No.:
09/186968
Inventors:
Jeffrey M. Leiden - Glencoe IL
Eliav Barr - St. Davids PA
Eliav Barr - St. Davids PA
Assignee:
Arch Development Corporation - Chicago IL
International Classification:
A01N 4304
US Classification:
514 44, 4353201, 435325, 435455, 536 235, 424 9321
Abstract:
The present invention relates to the use of adenovirus-mediated gene transfer to regulate function in cardiac and vascular smooth muscle cells. A recombinant adenovirus comprising a DNA sequence that codes for a gene product is delivered to a cardiac or vascular smooth muscle cell and the cell is maintained until that gene product is expressed. Delivery is direct injection into a muscle cell or infusing a pharmaceutical composition containing an adenovirus virus vector construct intravascularly.
Inducible Eukaryotic Expression System That Regulates Protein Translation
Inducible Eukaryotic Expression System That Regulates Protein Translation
US Patent:
2002008, Jul 4, 2002
Filed:
Mar 22, 2001
Appl. No.:
09/815980
Inventors:
Jeffrey Leiden - Glencoe IL, US
Deborah Marshall - Brookline MA, US
Deborah Marshall - Brookline MA, US
International Classification:
A61K031/70, C12N015/63
US Classification:
435/455000
Abstract:
A system for regulating the expression of a gene in a eukaryotic cell is provided, in which the expression of a desired gene can be activated or deactivated according to deliberate intentions (i.e., via an inducible signal) and in which regulation of gene expression occurs at the level of translation of the gene. This regulation is accomplished by, first, the introduction of at least one mutation into the coding sequence of the gene of interest. This mutation(s) causes a decrease or alteration of translation, and, hence, a decrease or alteration of expression of the desired gene. The method of the invention further involves contacting the eukaryotic cell containing the now mutated gene of interest with an agent that is able to suppress the effect of the mutation, thus allowing translation, and, hence, expression of the desired gene. Preferably, the method involves introduction of a stop codon mutation, which is suppressed by an aminoglycoside. Nucleic acid compositions for use in the system of the invention, and kits for carrying out the methods of the invention, are also provided.
Method And Apparatus For Determining Blood Parameters And Vital Signs Of A Patient
Method And Apparatus For Determining Blood Parameters And Vital Signs Of A Patient
US Patent:
2003021, Nov 13, 2003
Filed:
May 10, 2002
Appl. No.:
10/144224
Inventors:
Jeffrey Leiden - Glencoe IL, US
Omar Khalil - Libertyville IL, US
Eric Shain - Glencoe IL, US
Stanislaw Kantor - Buffalo Grove IL, US
Shu-jen Yeh - Grayslake IL, US
James Koziarz - Highland Park IL, US
Charles Hanna - Libertyville IL, US
Xiaomao Wu - Gurnee IL, US
Ronald Hohs - Kenosha WI, US
Omar Khalil - Libertyville IL, US
Eric Shain - Glencoe IL, US
Stanislaw Kantor - Buffalo Grove IL, US
Shu-jen Yeh - Grayslake IL, US
James Koziarz - Highland Park IL, US
Charles Hanna - Libertyville IL, US
Xiaomao Wu - Gurnee IL, US
Ronald Hohs - Kenosha WI, US
International Classification:
A61B005/00
US Classification:
600/323000
Abstract:
A method of monitoring a patient that comprises a non-invasive measurement of the hematocrit value or the concentration of hemoglobin coupled with the measurement of one or more vital signs. These vital signs include, but are not limited to, cardiac pulse rate, blood pressure, and arterial blood oxygenation. The invention also provides an apparatus for monitoring changes in the hematocrit value of a patient, in combination with one or more of the patient's vital signs.